

LITERATURLISTE, (96 ARTIKEL, KUMULATIVER IMPAKT FAKTOR: 539,2)

Als Letztautor (31 Artikel, total IF: 135,6)

Jahr	Publikation	Impaktfaktor (Jahr d. Veröffentl.)
2024	Unlocking Clinical Insights: Lymphocyte-Specific Protein Tyrosine Kinase Candidates as Promising Therapeutic Targets for Pancreatic Cancer Risk Stratification. Zhang H, Winter P, Wartmann T, Simioni L, Al-Madhi S, Perrakis A, Croner RS, Shi W, Yu Q, Kahlert UD . <i>Cancer Biother Radiopharm</i> . 2024 Jun 5.	2,4
2024	Nanoformulation of dasatinib cannot overcome therapy resistance of pancreatic cancer cells with low LYN kinase expression M Kaul, AY Sanin, W Shi, C Janiak, UD Kahlert <i>Pharmacol Rep</i> . 2024 Aug;76(4):793-806.	4,4
2023	Transient receptor potential channels as a predictive marker and potential indicator of chemoresistance in colon cancer H Wei, T Wartmann, M Strecker, A Perrakis, RS Croner, A Szallasi, W Shi, UD Kahlert <i>Oncology Research</i> . 2024, 32(1), 227-239	3,3
2023	Application of Machine Learning in the Diagnosis and Treatment of Endocrine Disorders H Zhang, UD Kahlert* and W Shi* <i>Front. Endocrinol</i> . 14:1305897., doi: 10.3389/fendo.2023.1305897	5,2
2024	Integrating a microRNA Signature as a Liquid Biopsy-Based Tool for early diagnosis and Potential Therapeutic Targets Prediction in Pancreatic Cancer W Shi, T Wartmann, S Accuffi, S Al-Madhi, A Perrakis, C Kahlert, A Link, M Venerito, V Keitel-Anselmino, C Bruns, RS Croner, Y Zhao, UD Kahlert <i>Br J Cancer</i> . 2024 Jan;130(1):125-134	8,8
2023	The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H NZ Mehjardi, J Kessler, A Sanin, D Picard, P Westhoff, Ann-Christin Nickel, C Uhlmann, W Shi, HJ Steiger, M Remke, I Fischer, D Vordermark, RS Croner and UD Kahlert <i>Cell Death Discov</i> . 2023 Dec 12;9(1):452	7,0
2023	Rapid, label-free classification of glioblastoma differentiation status combining confocal Raman spectroscopy and machine learning. L Wurm, B Fischer, V Neuschmelting, D Reinecke, I Fischer, RS Croner, R Goldbrunner, M Hacker, J Dybas, UD Kahlert <i>Analyst</i> . 2023 Nov 20;148(23):6109-6119.	4,4
2022	Meta-analysis on reporting practices as a source of heterogeneity in <i>in vitro</i> cancer research T Sander, J Ghanawi, E Wilson, S Muhammad, M Macleod and UD Kahlert <i>BMJ Open Sci</i> . 2022 Jun 1;6(1):e100272.	2,8
2022	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. Knauer N, Arkhipova V, Li G, Hewera M, Pashkina E, Nguyen PH, Meschaninova M, Kozlov V, Zhang W, Croner RS, Caminade AM, Majoral JP, Apartsin EK, Kahlert UD . <i>Int J Mol Sci</i> . 2022 May 19;23(10):5691.	6,2
2022	CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells. Poonaki E, Nickel AC, Shafiee Ardestani M, Rademacher L, Kaul M, Apartsin E, Meuth SG, Gorji A, Janiak C, Kahlert UD . <i>Int J Mol Sci</i> . 2022 May 13;23(10):5479.	6,2
2022	Progenitor cells derived from gene-engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology. Uhlmann C, Nickel AC, Picard D, Rossi A, Li G, Hildebrandt B, Brockerhoff G, Bendt F, Hübenthal U, Hewera M, Steiger HJ, Wiczorek D, Perrakis A, Zhang W, Remke M, Koch K, Tigges J, Croner RS, Fritsche E, Kahlert UD . <i>Biotechnol J</i> . 2022 Jun;17(6):e2100693.	4,7
2022	Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents. Shi W, Li C, Wartmann T, Kahlert C, Du R, Perrakis A, Brunner T, Croner RS, Kahlert UD . <i>J Pers Med</i> . 2022 Mar 16;12(3):478.	3,5
2022	Canonical WNT pathway inhibition reduces ATP synthesis rates in glioblastoma stem cells. Ouwens DM, Hewera M, Li G, Di W, Muhammad S, Hänggi D, Steiger HJ, Dumitru CA, Sandalcioğlu E, Croner RS, Zhang W, Kakhlon O, Kahlert UD . <i>Front Biosci (Landmark Ed)</i> . 2022 Jan 18;27(1):35	4,1
2021	Clinical Characterization and Immunosuppressive Regulation of CD161 (KLRB1) in Glioma through 916 Samples D Wang, W Fan, F Wu, Z Shi, Z Wang, M Yu, Y Zhai, Y Chang, C Pan, G Li*, UD Kahlert* , W Zhang*, *equal contribution <i>Cancer Science</i> 2021 Dec 8. doi: 10.1111/cas.15236.	6,7

2021	Reducing sources of variance in experimental procedures in in vitro research I Fischer, MV Martinez-Dominguez, D Hänggi and UD Kahlert <i>F1000Res. 2021 Oct 12;10:1037</i>	2,8
2021	Functional Clustering Analysis Identifies Specific Subtypes of Aldehyde Dehydrogenase Associated with Glioma Immunity D Wang; H Jiang; Z Wang; R Huang; T Jiang; UD Kahlert* , G Li*, W Zhang*, *equal contribution <i>Transl Cancer Res 2021 https://dx.doi.org/10.21037/tcr-21-1160</i>	1,3
2021	Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses. Nickel AC, Picard D, Qin N, Wolter M, Kaulich K, Hewera M, Pauck D, Marquardt V, Torga G, Muhammad S, Zhang W, Schnell O, Steiger HJ, Hänggi D, Fritsche E, Her NG, Nam DH, Carro MS, Remke M, Reifemberger G, Kahlert UD. <i>Biomed Pharmacother. 2021 Dec;144:112278.</i>	6,6
2021	Testing the Stability of Drug Resistance on Cryopreserved, Gene-Engineered Human Induced Pluripotent Stem Cells. Khan D, Nickel AC, Jeising S, Uhlmann C, Muhammad S, Hänggi D, Fischer I, Kahlert UD. <i>Pharmaceuticals (Basel). 2021 Sep 11;14(9):919.</i>	5,8
2021	A Preclinical Pipeline for Translational Precision Medicine-Experiences from a Transdisciplinary Brain Tumor Stem Cell Project. Vargas-Toscano A, Janiak C, Sabel M, Kahlert UD. <i>J Pers Med. 2021 Sep 7;11(9):892.</i>	4,8
2021	eLabFTW as an Open Science tool to improve the quality and translation of preclinical research M Hewera, D Hänggi, B Gerlach and UD Kahlert <i>F1000Research, accepted July 29th</i>	2,7
2021	Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery B Giesen, AC Nickel, J Barthel, UD Kahlert* and C Janiak*, *equal contribution, <i>Pharmaceutics, 2021, 13, 295. https://doi.org/10.3390/pharmaceutics13020295</i>	4,6
2021	Carbonic anhydrase XII is a clinical significant, molecular tumor-subtype specific therapeutic target in glioma with potential to combat invasion of brain tumor cells G Li, TW Chen, AC Nickel, S Muhammad, HJ Steiger, T Tzaridis, D Hänggi, R Zeidler, W Zhang and UD Kahlert <i>OncoTargets and Therapy, 2021(14)1707—1718</i>	3,3
2020	Rapalink-1 targets glioblastoma stem cells and acts synergistically with Tumor Treating Fields to reduce resistance against temozolomide A Vargas-Toscano, AC Nickel, G Li, MA Kamp, S Muhammad, G Leprivier, E Fritsche, RA Barker, M Sabel, HJ Steiger, W Zhang, D Hänggi and UD Kahlert <i>Cancers, Dec 21;12(12):E3859. doi: 10.3390/cancers12123859</i>	6,3
2020	Different calculation strategies are congruent in determining chemotherapy resistance of brain tumors <i>in vitro</i> I Fischer, AC Nickel, N Qin, D Pauck, K Taban, HJ Steiger, M Kamp, S Muhammad, D Hänggi, E Fritsche, M Remke and UD Kahlert <i>Cells 2020, 9(12), 2689; 10.3390/cells9122689</i>	4,2
2020	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma D Herrera-Rios, G Li, D Khan, J Tsiampali, AC Nickel, P Aretz, M Hewera, AK Suwala, T Jiang, HJ Steiger, MA Kamp, S Muhammad, D Hänggi, J Maciacyk W Zhang and UD Kahlert <i>Scientific Reports, Sci Rep. 2020 Oct 1;10(1):16218. doi: 10.1038/s41598-020-72480-y</i>	4,1
2020	An inexpensive and easy-to-implement approach to a QMS for an academic research lab M Hewera, AC Nickel, N Knipprath, S Muhammad, X Fan, HJ Steiger, D Hänggi and UD Kahlert <i>F1000Research 30 Jun 2020, 9:660 DOI 10.12688/f1000research.24494.1</i>	2,6
2020	Robot technology identifies a Parkinsonian therapeutics repurpose to target stem cells of glioblastoma A Vargas-Toscano, AC Nickel, M Hewera, MA Kamp, I Fischer, HJ Steiger ¹ , W Zhang, S Muhammad, D Hänggi and UD Kahlert <i>CNS Oncol 28 May 2020 DOI 10.2217/cns-2020-0004.</i>	2,0
2020	A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity K Koch, R Hartmann, N Tsiampali, C Uhlmann, AC Nickel, X He, MA Kamp, M Sabel, R Barker, HJ Steiger, D Hänggi, D Willbold, J Maciacyk and UD Kahlert <i>Cell Death Discov. 2020 Apr 16;6:20.</i>	4,2
2020	Efficient Modulation of TP53 Expression in Human Induced Pluripotent Stem Cells. C Uhlmann, LM Kuhn, J Tigges, E Fritsche and UD Kahlert <i>Curr Protoc Stem Cell Biol. 2020 Mar;52(1):e102.</i>	1,0
2019	Influence of synthesis methods on the internalization of fluorescent gold nanoparticles into glioblastoma stem-like cells.	3,3

	B Giesen, AC Nickel, A Garzón Manjón, A Vargas Toscano, C Scheu, UD Kahlert* C Janiak* . *equal contribution <i>J Inorg Biochem.</i> 2019 Nov 23;203:110952.	
2017	CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemo resistance of EMT-like glioblastoma cells. D Maciaczyk, D Picard, L Zhao, K Koch, D Herrera-Rios, G Li, V Marquardt, D Pauck, T Hoerbelt, W Zhang, MD Ouwens, M Remke, T Jiang, HJ Steiger, J Maciaczyk and UD Kahlert . <i>British Journal of Cancer [Br J Cancer]</i> . 2017 Jun27;117(1):102-112	6,2

Als Erstautor (8 Artikel, total IF: 36,1)

2022	COL10A1 allows stratification of invasiveness of colon cancer and associates to extracellular matrix and immune cell enrichment in the tumor parenchyma Kahlert UD , Shi W, Strecker M, Scherpinski LA, Wartmann T, Dölling M, Perrakis A, Relja B, Mengoni M, Braun A, Croner RS. <i>Front Oncol.</i> 2022 Oct 4;12:1007514.	5,7
2016	Alterations in Cellular Metabolome after Pharmacological Inhibition of Notch in Glioblastoma Cells UD Kahlert , M Cheng, K Koch, X Fan, L Marchionni, J Maciaczyk, K Glunde and CG Eberhart. <i>International Journal of Cancer [Int J Cancer]</i> 2016 Mar; 138 (5) 1246–1255.	6,5
2015	The Effect of Neurosphere Culture Conditions on Cellular Metabolism of Glioma cells UD Kahlert , K Koch, R Hartmann, M Cheng, D. Maciaczyk, M Natsumeda, CG Eberhart, D Willbold, K Glunde, and J Maciaczyk. <i>Folia Neuropathologica [Folia Neuropath.]</i> , 2015;53(3):219-25	1,2
2015	Pharmacological WNT inhibition reduces proliferation, survival and clonogenicity of Glioblastoma cells UD Kahlert , AK Suwala, K Koch, M Hayashi, M Natsumeda, J Maciaczyk and CG Eberhart. <i>Journal Neuropathology and Experimental Neurology</i> .2015 Sep;74(9):889-900.	3,4
2015	ZEB1 promotes invasion in human fetal neural stem cells and hypoxic glioma neurospheres UD Kahlert AK, Suwala, EH Raabe, FA Siebzehrnubel, MJ Suarez, BA Orr, EE Bar, J Maciaczyk, CG Eberhart. <i>Brain Pathology [Brain Pathol.]</i> 2015 Nov;25(6):724-732.	5,3
2012	Resistance to Hypoxia-Induced, BNIP3-mediated Cell Death Contributes to an Increase in a CD133-Positive Cell Population In Human Glioblastomas <i>In Vitro</i> UD Kahlert , D Maciaczyk, F Dai, R Claus, E Firat, S Doostkam, T Bogiel, MS Carro, M Döbrössy, C Herold-Mende, G Niedermann, M Prinz, G Nikkhah and J Maciaczyk. <i>[J Neuropathol Exp Neurol.]</i> 2012 Dec;71(12):1086-99.	3,6
2012	CD133/CD15 defines distinct cell subpopulations with differential <i>in vitro</i> clonogenic activity and stem cell-related gene expression profile in <i>in vitro</i> propagated glioblastoma multiforme-derived cell line UD Kahlert , N Bender, D Maciaczyk, E Bar, CG Eberhart, G Nikkhah and J. Maciaczyk. <i>[Folia Neuropathol.]</i> 2012;50(4):357-68	1,2
2012	Activation of canonical WNT/ β -catenin signaling enhances <i>in vitro</i> motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. UD Kahlert , D Maciaczyk, S Doostkam, BA Orr, B Simons, T Bogiel, T Reithmeier, M Prinz, J Schubert, G Niedermann, T Brabletz, CG Eberhart, G Nikkhah and J Maciaczyk. <i>Cancer Letters [Cancer Lett.]</i> 2012 Dec 1;325(1):42-53.	4,8

Als Ko-Autor (42 Artikel, total IF: 302,1)

2024	Editorial: lncRNAs: application in immunotherapy, radiotherapy, and chemotherapy. Cheng H, Kahlert UD , Shi W. <i>Front Cell Dev Biol.</i> 2024 Jul 25;12:1438773.	4,6
2024	Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Li G, Wang D, Zhai Y, Pan C, Zhang J, Wang C, Huang R, Yu M, Li Y, Liu X, Liu Y, Wu F, Zhao Z, Hu H, Shi Z, Kahlert UD , Jiang T, Zhang W. <i>Cell Metab.</i> 2024 Aug 6;36(8):1696-1710.e10	29
2024	Hidden Appendicoliths and Their Impact on the Severity and Treatment of Acute Appendicitis. Dölling M, Rahimli M, Pachmann J, Szep M, Al-Madhi S, Andric M, Kahlert UD , Hofmann T, Boettcher M, Muñoz LE, Hermann M, Perrakis A, Croner RS. <i>J Clin Med.</i> 2024 Jul 16;13(14):4166.	3,0
2024	4EBP1/2 support tumorigenicity and cell survival during energetic stress by translationally regulating fatty acid synthesis T Levy, K Voeltzke, L Hauffe, K Alasad, M Snaebjörnsson, R Marciano, K Scharov, M Planque, K Vriens, S Christen, CM Funk, C Hassiepen, A Kahler, B Heider, D Picard, JKM Lim, Z Bas, K Bendrin, A Vargas-Toscano, UD Kahlert, M Remke, M Elkabets, TGP Grünwald, AS Reichert, S-M Fendt, A Schulze, G Reifemberger, B Rotblat, G Leprivier <i>Nat. Communications (accepted 12 February)</i>	16,6
2023	Seven oxidative stress-related genes predict the prognosis of hepatocellular carcinoma C Miao, X He, G Chen, UD Kahlert , C Yao, W Shi, D Su, L Hu, Z Zhang <i>Aging (US)</i> , 2023 Dec 14;15. doi: 10.18632/aging.205330	5,2
2023	Concept of a fully-implantable system to monitor tumor recurrence. Schauffer A, Sanin AY, Sandalcioğlu IE, Hartmann K, Croner RS, Perrakis A, Wartmann T, Boese A, Kahlert UD , Fischer I. <i>Sci Rep.</i> 2023 Sep 29;13(1):16362	4,6

2023	Oxidative stress genes define two subtypes of triple-negative breast cancer with prognostic and therapeutic implications. Liu S, Xu H, Feng Y, Kahlert UD , Du R, Torres-de la Roche LA, Xu K, Shi W, Meng F. <i>Front Genet.</i> 2023 Jul 13;14:1230911.	3,7
2023	Mendelian Randomization Analyses of Chronic Immune-Mediated Diseases, Circulating Inflammatory Biomarkers, and Cytokines in Relation to Liver Cancer. Yin Q, Yang Q, Shi W, Kahlert UD , Li Z, Lin S, Song Q, Fan W, Wang L, Zhu Y, Huang X. <i>Cancers (Basel).</i> 2023 May 26;15(11):2930.	5,2
2023	Effects of Dendrimer-microRNA Nanoformulations against Glioblastoma Stem Cells. Knauer N, Meschaninova M, Muhammad S, Hänggi D, Majoral JP, Kahlert UD , Kozlov V, Apartsin EK. <i>Pharmaceutics.</i> 2023 Mar 17;15(3):968	5,4
2023	Chromatin Regulator-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Breast Cancer. Feng D, Li W, Wu W, Kahlert UD , Gao P, Hu G, Huang X, Shi W, Li H. <i>J Oncol.</i> 2023 Jan 30;2023:2736932.	4,5
2023	Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma. Han Y, Drobisch P, Krüger A, William D, Grützmann K, Böthig L, Polster H, Seifert L, Seifert AM, Distler M, Pecqueux M, Riediger C, Plodeck V, Nebelung H, Weber GF, Pilarsky C, Kahlert UD , Hinz U, Roth S, Hackert T, Weitz J, Wong FC, Kahlert C. <i>J Hematol Oncol.</i> 2023 Feb 3;16(1):7	22
2023	Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blümel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, Wölfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert UD , Stefanski A, Stühler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakkar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra S. <i>J Immunother Cancer.</i> 2023 Jan;11(1):e005871.	12,5
2022	MET fusions and splicing variants convergently define a subgroup of glioma sensitive to MET inhibitors. Zhang KN, Zheng Z, Chen J, Boa Z, Chai RC, Sun Z, ..., Kahlert UD , et al. <i>Holist Integ Oncol</i> 1, 18 (2022).	-
2022	MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. Wang G, Miao C, Mo L, Kahlert UD , Wu J, Ou M, Huang R, Feng R, Pang W, Shi W. <i>Front Immunol.</i> 2022 Dec 13;13:1048503.	8,8
2022	Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia. Lenk L, Winterberg D, Vogiatzi F, Laqua A, Spory L, Mayar A, Dietterle A, Münch G, Vokuhl C, Richter J, Polson AG, Schüller T, Kahlert UD , Peipp M, Valerius T, Schrappe M, Cario G, Jumaa H, Hobeika E, Brüggemann M, Alsadeq A, Schewe DM. <i>Hemasphere.</i> 2022 Jul 15;6(8):e754	8,3
2022	A Novel Extracellular Matrix Gene-Based Prognostic Model to Predict Overall Survive in Patients With Glioblastoma. Qian C, Xiufu W, Jianxun T, Zihao C, Wenjie S, Jingfeng T, Kahlert UD , Renfei D. <i>Front Genet.</i> 2022 Jun 17;13:851427.	4,7
2022	Construction of ceRNA Networks Associated With CD8 T Cells in Breast Cancer. Chen Z, Feng R, Kahlert UD , Chen Z, Torres-Dela Roche LA, Soliman A, Miao C, De Wilde RL, Shi W. <i>Front Oncol.</i> 2022 Jun 9;12:883197.	6,2
2022	Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey. Kebir S, Lazaridis L, Wick W, Platten M, Tabatabai G, Combs SE, Schmidt T, Agkatsev S, Blau T, Mäurer I, Kahlert U , Sagerer A, Berberich A, Heider S, Mütther M, Bodensohn R, Behling F. <i>Neuro Oncol.</i> 2022 May 27;noac114. doi: 10.1093/neuonc/noac114.	12,3
2022	Amphiphilic Triazine-Phosphorus Metallo dendrons Possessing Anti-Cancer Stem Cell Activity. Apartsin EK, Knauer N, Kahlert UD , Caminade AM. <i>Pharmaceutics.</i> 2022 Feb 10;14(2):393.	6,5
2022	Multifaceted Analyses of Isolated Mitochondria Establish the Anticancer Drug 2-Hydroxyoleic Acid as an Inhibitor of Substrate Oxidation and an Activator of Complex IV-Dependent State 3 Respiration. Mishra K, Péter M, Nardiello AM, Keller G, Llado V, Fernandez-Garcia P, Kahlert UD , Barasch D, Saada A, Török Z, Balogh G, Escriba PV, Piotto S, Kakhlon O. <i>Cells.</i> 2022 Feb 7;11(3):578.	7,7

2021	Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism C Wilms, K Lepka, F Häberlein, S Edwards, J Felsberg, L Pudelko, TT Lindenberg, G Poschmann, N Qin, K Volbracht, T Prozorovski, SG Meuth, UD Kahlert , M Remke, O Aktas, G Reifenberger, L Bräutigam, B Odermatt, C Berndt. <i>Redox Biol.</i> 2021 Dec 21;49:102221.	11,8
2021	Overexpression of Cystine/Glutamate Antiporter xCT Correlates with Nutrient Flexibility and ZEB1 Expression in Highly Clonogenic Glioblastoma Stem-like Cells K Koch, R Hartmann, R Hartmann, AK Suwala, D Herrera-Rios, MA Kamp, M Sabel, HJ Steiger, D Willbold, Amit Sharma, UD Kahlert and J Maciaczyk <i>Cancers</i> , 13(23), 6001	6,6
2021	Differential polarization and activation dynamics of systemic T helper cell subsets after aneurysmal subarachnoid hemorrhage (SAH) and during post-SAH complications SR Chaudhry, UD Kahlert , TM Kinfe, E Endl, A Dolf, M Niemelä, D Hänggi and S Muhammad <i>Sci Rep.</i> 2021 Jul 9;11(1):14226	4,0
2021	Brain Immune Interactions- Novel Emerging Options to Treat Acute Ischemic Brain Injury. Muhammad S, Chaudhry SR, Kahlert UD , Niemelä M, Hänggi D. <i>Cells.</i> 2021 Sep 15;10(9):2429.	6,6
2021	BCOR Internal Tandem Duplication Expression in Neural Stem Cells Promotes Growth, Invasion and Expression of PRC2 Targets S Nakata, M Yuan, JA Rubens, UD Kahlert , J Maciaczyk, EH Raabe and CG Eberhart <i>Int J Mol Sci.</i> 2021 Apr 10;22(8):3913. doi: 10.3390/ijms22083913	4,6
2021	Proposed definition of competencies for surgical neuro-oncology training MA Kamp, ..., UD Kahlert , et al. <i>Journal of Neurooncology</i> , accepted March 26 th 2021	3,3
2021	Systemic inflammatory index (SII) is a novel predictor of intubation requirement and mortality after COVID-19 infection S Muhammad, I Fischer, S Naderi, M Faghih, Sh Abdolreza, E Karimialavijeh, S Aslzadeh, M Mashayekhi, M Zojaji, UD Kahlert and D Hänggi <i>Pathogens</i> , 2021 Jan 11;10(1):58	3,6
2021	Uronic acid metabolic process-related gene expression-based signature predicts overall survival of glioma Y Feng, G Li, Z Shi, X Yan, R Li, Y Zhai, Y Chang, D Wang, UD Kahlert UD , F Yuan, W Zhang <i>Bioscience Reports</i> , 2021 Jan 29;41(1):BSR20203051	2,9
2020	Association between health insurance status and malignant glioma I Fischer, HJ Mijderwijk, UD Kahlert , M Rapp, M Sabel, D Hänggi, HJ Steiger, MT Forster, MA Kamp <i>Neuro-Oncology Practice</i> Jun 6;7(5):531-540	1,4
2020	Elevated Systemic IL-10 Levels Indicate Immunodepression Leading to Nosocomial Infections after Aneurysmal Subarachnoid Hemorrhage (SAH) in Patients. SR Chaudhry, UD Kahlert , TM Kinfe, A Lamprecht, M Niemelä, D Hänggi, S Muhammad. <i>Int J Mol Sci.</i> 2020 Feb 25;21(5).	4,2
2019	Exploiting tumor-intrinsic signals to induce mesenchymal stem cell-mediated suicide gene therapy to fight malignant glioma. M Li, S Sun, S Dangelmajer, Q Zhang, J Wang, F Hu, F Dong, UD Kahlert , M Zhu, T Lei. <i>Stem Cell Res Ther.</i> 2019 Mar 12;10(1):88.	4,6
2019	Transforming Growth Factor- β Promotes Homing and Therapeutic Efficacy of Human Mesenchymal Stem Cells to Glioblastoma. M Li, L Zeng, S Liu, S Dangelmajer, UD Kahlert , H Huang, Y Han, X Chi, M Zhu, T Lei. <i>J Neuropathol Exp Neurol.</i> 2019 Apr 1;78(4):315-325.	3,5
2019	Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-MYC medulloblastoma. M Natsumeda, Y Liu, S Nakata, H Miyahara, A Hanaford, S Ahsan, D Stearns, N Skuli, UD Kahlert , EH Raabe, FJ Rodriguez, Eberhart CG. <i>Neuropathology.</i> 2019 Apr;39(2):71-77.	2,2
2018	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. G Li, Y Li, X Liu, Z Wang, C Zhang, F Wu, H Jiang, W Zhang, Z Bao, Y Wang, J Cai, L Zhao, UD Kahlert , T Jiang, W Zhang. <i>Cell Death Dis.</i> 2018 Dec 11;9(12):1190.	6,0
2018	AK Suwala, K Koch, DH Rios, P Aretz, C Uhlmann, I Ogorek, J Felsberg, G Reifenberger, K Köhrer, R Deenen, HJ Steiger, UD Kahlert , J Maciaczyk. Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma <i>in vitro</i> . <i>Oncotarget [Oncotarget]</i> , 2018 Apr 27;9(32):22703-22716	4,6
2017	M Hayashi, A Baker, SD Goldstein, CM Albert, KW Jackson, G McCarty, UD Kahlert and DM Loeb.	4,6

	Inhibition of Porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma <i>Oncotarget. 2017 Jul 21;8(45):78265-78276</i>	
2017	S Semenkow, S Li, UD Kahlert , EH Raabe, J Xu, A Arnold, M Janowski, BC Oh, G Brandacher, JW Bulte, CG Eberhart and P Walczak. An immunocompetent mouse model of human glioblastoma <i>Oncotarget 2017 May 15;8(37):61072-61082</i>	4,6
2016	K Koch, R Hartmann, F Schroeter, AK Suwala, D Maciaczyk, AC Krueger, D Willbold, UD Kahlert and J Maciaczyk. Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells <i>Oncotarget. 2016 Nov 8;7(45):73414-73431.</i>	5,1
2016	M Zhu, M Li, Y Zhou, S Dangelmajer, UD Kahlert , R Xie, Q Xi, A Shahveranov, D Ye, T Lei. Isoflurane enhances the malignant potential of glioblastoma stem cells by promoting their viability, mobility in vitro and migratory capacity <i>in vivo</i> . <i>British Journal of Anaesthesia [Br J Anaesth.] 2016 Jun;116(6):870-7.</i>	5,6
2016	A Hanaford, TC Archer, A Price, UD Kahlert , J Maciaczyk, G Nikkhah, W Kim, T Ehrenberger, P Clemons, V Dančik, B Seashore-Ludlow, V Viswanathan, ML Stewart, M Rees, A Shamji, W Hahn, S Schreiber, E Fraenke, SL Pomeroy, JP Mesirov, P Tamayo, CG Eberhart, EH Raabe. DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with <i>in silico</i> analysis to identify novel therapeutic targets <i>Clinical Cancer Research [Clin Cancer Res.] 2016 Aug 1;22(15):3903-14.</i>	9,6
2016	M Natsumeda, K Maitani , Y Liu, H Miyahara, H Kaur, Q Chu, H Zhang, UD Kahlert , CG Eberhart. Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres. <i>Brain Pathology [Brain Pathol.] 2016 Nov;26(6):713-723.</i>	5,4
2015	T Shiraishi, J Huang, J Verdone, UD Kahlert , J Hernandez , G Torga , J Zarif , T Epstein, R Gatenby , A McCartney, J Elisseeff, S Mooney, S An and K Pienta. Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells <i>Oncotarget. 2015 Jan 1;6(1):130-43.</i>	5,0
2014	M Schmidt, UD Kahlert , J Wessolleck, D Maciaczyk, B Merkt, J Maciaczyk, J Osterholz, G Nikkhah and MO Steinhauser. Characterization of a Setup to test the Impact of High-Amplitude Pressure Waves on Living Cells. <i>Scientific Reports [Sci Rep.] 2014 Jan 24;4:3849</i>	5,6
2013	XG Mao, M Hütt-Cabezas, BA Orr, M Weingart, I Taylor, AK Rajan, Y Odia, UD Kahlert , J Maciaczyk, G Nikkhah, CG Eberhart and EH Raabe. <i>LIN28A</i> facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. <i>Oncotarget. 2013 Jul;4(7):1050-64.</i>	6,6
2013	WO Lopez, G Nikkhah, UD Kahlert , D Maciaczyk, T Bogiel, S Moellers, E Schültke, M Döbrössy, Maciaczyk J. Clinical neurotransplantation protocol for Huntington's and Parkinson's disease. Restorative Neurology and Neuroscience <i>[Restor Neurol Neurosci.] 2013 Jun 18.</i>	2018: 2,0
2012	N Baxan, UD Kahlert , J Maciaczyk, G Nikkhah, J Hennig, D von Elverfeldt. Microcoil-based MR phase imaging and manganese enhanced microscopy of glial tumor neurospheres with direct optical correlation. <i>Magnetic Resonance in Medicine [Magn Reson Med.] 2012 Jul;68(1):86-97.</i>	3,5
2011	EH Raabe, KS Lim, JM Kim, A Meeker, XG Mao, G Nikkhah, J Maciaczyk, UD Kahlert , D Jain, EE Bar, KJ Cohen and CG Eberhart. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. <i>[Clin Cancer Res.] 2011 Jun 1;17(11):3590-9.</i>	8,0

Übersichtsartikel (11 Artikel, total IF 63,5)

2022	The role of the ZEB1-neuroinflammation axis in CNS disorders Poonaki E, Kahlert UD , Meuth SG, Gorji A. <i>J Neuroinflammation</i> . 2022 Nov 19;19(1):275	9,5
2022	Artificial Ovary for Young Female Breast Cancer Patients. Chen J, Torres-de la Roche LA, Kahlert UD , Isachenko V, Huang H, Hennefründ J, Yan X, Chen Q, Shi W, Li Y. <i>Front Med (Lausanne)</i> . 2022 Mar 17;9:837022.	5,1
2021	Current Technologies for RNA-Directed Liquid Diagnostics. Martinez-Dominguez MV, Zottel A, Šamec N, Jovčevska I, Dincer C, Kahlert UD , Nickel AC. <i>Cancers (Basel)</i> . 2021 Oct 10;13(20):5060.	6,4
2021	Brain Immune Interactions- Novel Emerging Options to Treat Acute Ischemic Brain Injury. Muhammad S, Chaudhry SR, Kahlert UD , Niemelä M, Hänggi D. <i>Cells</i> . 2021 Sep 15;10(9):2429	6,6
2021	Role of Adaptor Protein Myeloid differentiation 88 (MyD88) in Post-Subarachnoid Hemorrhage inflammation: a systematic review H Ahmed, MA Khan, UD Kahlert , M Niemelä, D Hänggi, SR Chaudhry and S Muhammad <i>Int J Mol Sci</i> , accepted April 4th	4,6
2020	Current biomarker –associated procedures of cancer modeling- a reference in the context of IDH1 mutant glioma NZ Mehrjardi, D Hänggi and UD Kahlert <i>Cell Death & Disease</i> , Nov 21;11(11):998.	6,0
2020	Targeting High Mobility Group Box 1 in Subarachnoid Hemorrhage: A Systematic Review Muhammad S, Chaudhry SR, Kahlert UD , Lehecka M, Korja M, Mika Niemelä M, Hänggi D <i>Int J Mol Sci</i> . 2020 Apr 14;21(8). pii: E2709.	4,2
2017	EMT and MET-related processes in non-epithelial tumors: importance for disease progression, prognosis and therapeutic opportunities. UD Kahlert , J Joseph and FA Krut. <i>Molecular Oncology [Mol Oncol.]</i> 2017 Jul;11(7):860-877.	5,4
2017	Targeting Cancer Stem-like Cells in Glioblastoma and Colorectal Cancer through Metabolic Pathways UD Kahlert , SM Mooney, M Natsumeda, HJ Steiger and J Maciaczyk. <i>[Int J Cancer.]</i> 2017 Jan 1;140(1):10-22.	7,3
2016	AK Suwala, A Hanaford, UD Kahlert and J Maciaczyk. Clipping the Wings of Glioblastoma: Modulation of WNT As A Novel Therapeutic Strategy <i>[J Neuropathol Exp Neurol.]</i> , 2016 May;75(5):388-96	3,4
2013	UD Kahlert , G Nikkhah and J Maciaczyk. Epithelial-to-mesenchymal transition (-like) is a Relevant Molecular Event in malignant gliomas <i>Cancer Lett</i> . 2013 May 1;331(2):131-8.	5,0

Buchkapitel:

2014	J. Maciaczyk, UD Kahlert , M Döbrössy and G Nikkhah, Stereotactic Surgery in Rats, Springer Protocols, Experimental Neurosurgery in Animals, Humana Press, New York, NY, pages 31-54
------	---